The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia
Abstract
IMPORTANCE: Glycemic targets in diabetes have been developed to minimize complication risk. Patients with heterozygous, inactivating glucokinase (GCK) mutations have mild fasting hyperglycemia from birth, resulting in an elevated glycated hemoglobin (HbA1c) level that mimics recommended levels for type 1 and type 2 diabetes. OBJECTIVE: To assess the association between chronic, mild hyperglycemia and complication prevalence and severity in patients with GCK mutations. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in the United Kingdom between August 2008 and December 2010. Assessment of microvascular and macrovascular complications in participants 35 years or older was conducted in 99 GCK mutation carriers (median age, 48.6 years), 91 nondiabetic, familial, nonmutation carriers (control) (median age, 52.2 years), and 83 individuals with young-onset type 2 diabetes (YT2D), diagnosed at age 45 years or younger (median age, 54.7 years). MAIN OUTCOMES AND MEASURES: Prevalence and severity of nephropathy, retinopathy, peripheral neuropathy, peripheral vascular disease, and cardiovascular disease. RESULTS: Median HbA1c was 6.9% in patients with the GCK mutation, 5.8% in controls, and 7.8% in patients with YT2D. Patients with GCK had a low prevalence of clinically significant microvascular complications (1% [95% CI, 0%-5%]) that was not significantly different from controls (2% [95% CI, 0.3%-8%], P=.52) and lower than in patients with YT2D (36% [95% CI, 25%-47%], P<.001). Thirty percent of patients with GCK had retinopathy (95% CI, 21%-41%) compared with 14% of controls (95% CI, 7%-23%, P=.007) and 63% of patients with YT2D (95% CI, 51%-73%, P<.001). Neither patients with GCK nor controls required laser therapy for retinopathy compared with 28% (95% CI, 18%-39%) of patients with YT2D (P<.001). Neither patients with GCK patients nor controls had proteinuria and microalbuminuria was rare (GCK, 1% [95% CI, 0.2%-6%]; controls, 2% [95% CI, 0.2%-8%]), whereas 10% (95% CI, 4%-19%) of YT2D patients had proteinuria (P<.001 vs GCK) and 21% (95% CI, 13%-32%) had microalbuminuria (P<.001). Neuropathy was rare in patients with GCK (2% [95% CI, 0.3%-8%]) and controls (95% CI, 0% [0%-4%]) but present in 29% (95% CI, 20%-50%) of YT2D patients (P<.001). Patients with GCK had a low prevalence of clinically significant macrovascular complications (4% [95% CI, 1%-10%]) that was not significantly different from controls (11% [95% CI, 5%-19%]; P=.09), and lower in prevalence than patients with YT2D (30% [95% CI, 21%-41%], P<.001). CONCLUSIONS AND RELEVANCE: Despite a median duration of 48.6 years of hyperglycemia, patients with a GCK mutation had low prevalence of microvascular and macrovascular complications. These findings may provide insights into the risks associated with isolated, mild hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 6×
“2-7]) 5/91 (5 [2-13]) 13/83 (16 [10-29]) .”
InfluentialTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.
Rose, G. A. (1962) · Europe PMC (PubMed Central) · Cited by 1,320
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202 · cited 7×
“2-7]) 5/91 (5 [2-13]) 13/83 (16 [10-29]) .”
InfluentialKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Coronary heart disease statistics.
Allender, S. E., Peto, V., Scarborough, P., Kaur, A., & Rayner, M. (2008) · Deakin Research Online (Deakin University) · Cited by 928
MICROALBUMINURIA AS PREDICTOR OF VASCULAR DISEASE IN NON-DIABETIC SUBJECTS
Yudkin, J., Forrest, R., & Jackson, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92657-8 · Cited by 847
Hillege, H. L., Janssen, W. M. T., Bak, A. A. A., Diercks, G. F. H., Grobbee, D. E., Crijns, H. J. G. M., Van Gilst, W. H., De Zeeuw, D., De Jong, P. E., & FOR THE PREVEND STUDY GROUP (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00833.x · Cited by 629
Gregg, E. W., Sorlie, P., Paulose-Ram, R., Gu, Q., Eberhardt, M. S., Wolz, M., Burt, V., Curtin, L., Engelgau, M., & Geiss, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1591 · Cited by 585
The Minnesota Code Manual of Electrocardiographic Findings
Prineas, R. J., Crow, R. S., & Zhang, Z.-M. (2010) · Springer eBooks · doi:10.1007/978-1-84882-778-3 · Cited by 563
Blood Pressure, Lipids, and Obesity Are Associated With Retinopathy
van Leiden, H. A., Dekker, J. M., Moll, A. C., Nijpels, G., Heine, R. J., Bouter, L. M., Stehouwer, C. D. A., & Polak, B. C. P. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1320 · Cited by 414
Criqui, M. H., Denenberg, J. O., Bird, C. E., Fronek, A., Klauber, M. R., & Langer, R. D. (1996) · Vascular Medicine · doi:10.1177/1358863x9600100112 · Cited by 348
Minnesota Code Manual of Electrocardiographic Findings
Marty, A. T. (1983) · Critical Care Medicine · doi:10.1097/00003246-198307000-00029 · Cited by 310
Effect of Outliers and Nonhealthy Individuals on Reference Interval Estimation
Horn, P. S., Feng, L., Li, Y., & Pesce, A. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.12.2137 · Cited by 301
The genetic abnormality in the beta cell determines the response to an oral glucose load
Stride, A., Vaxillaire, M., Tuomi, T., Barbetti, F., Njølstad, P. R., Hansen, T., Costa, A., Conget, I., Pedersen, O., Søvik, O., et al. (2002) · Diabetologia · doi:10.1007/s00125-001-0770-9 · Cited by 277
Self-citationVelho, G., Blanché, H., Vaxillaire, M., Bellanné-Chantelot, C., Pardini, V. C., Timsit, J., Passa, P., Deschamps, I., Robert, J.-J., Weber, I. T., et al. (1997) · Diabetologia · doi:10.1007/s001250050666 · Cited by 266
Byrne, M. M., Sturis, J., Menzel, S., Yamagata, K., Fajans, S. S., Dronsfield, M. J., Bain, S. C., Hattersley, A. T., Velho, G., Froguel, P., et al. (1996) · Diabetes · doi:10.2337/diab.45.11.1503 · Cited by 259
Self-citationStride, A., Shields, B., Gill-Carey, O., Chakera, A. J., Colclough, K., Ellard, S., & Hattersley, A. T. (2014) · Diabetologia · doi:10.1007/s00125-013-3075-x · Cited by 212
Self-citationNathan, D. M., & for the American Diabetes Association and European Association for the Study of Diabetes Consensus Committee (2009) · Diabetes Care · doi:10.2337/dc09-0271 · Cited by 201
Gregg, E. W., Gu, Q., Williams, D. E., de Rekeneire, N., Cheng, Y. J., Geiss, L. S., & Engelgau, M. M. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.005 · Cited by 134
Steele, A. M., Wensley, K. J., Ellard, S., Murphy, R., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Shields, B. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065326 · Cited by 133
Self-citationGlycated hemoglobin as a marker of cardiovascular risk
Khaw, K., & Wareham, N. J. (2006) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3280106b95 · Cited by 119
Diabetes Complications in NIDDM Kindreds Linked to the MODY3 Locus on Chromosome 12q
Velho, G., Vaxillaire, M., Boccio, V., Charpentier, G., & Froguel, P. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.915 · Cited by 100
Klein, R., Klein, R., Moss, S. E., & Wong, T. Y. (2006) · Europe PMC (PubMed Central) · Cited by 95
Diagnostic screening of MODY2/GCKmutations in the Norwegian MODY Registry
Sagen, J. V., Bjørkhaug, L., Molnes, J., Ræder, H., Grevle, L., Sövik, O., Molven, A., & Njølstad, P. R. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00399.x · Cited by 57
Clinical Characteristics of Subjects with a Missense Mutation in Glucokinase
Page, R. C., Lévy, J., Barrow, B. A., Turner, R. C., Patel, P., Hattersley, A. T., Lo, D., Wainscoat, J. S., Permutt, M. A., & Bell, G. I. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00460.x · Cited by 55
Self-citation
Cited by
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“is rarely associated with chronic microvascular or macrovascular complications of diabetes (118, 119) and patients do not generally require any treatment (120) except in the setting of pregnancy where an affected mother has an unaffected fetus and there is in utero evidence of macrosomia (121) .”
Self-citationInsulin resistance is a cardiovascular risk factor in humans
Adeva-Andany, M. M., Martínez-Rodríguez, J., González-Lucán, M., Fernández-Fernández, C., & Castro-Quintela, E. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.02.023 · Cited by 313
Precision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
Self-citationDiabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Metadata
- Authors
- Steele, A. M., Shields, B. M., Wensley, K. J., Colclough, K., Ellard, S., & Hattersley, A. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-01-15
- Volume
- 311
- Issue
- 3
- Pages
- 279
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2040195150
- Cited by
- 381
- References
- 35
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.